Latest Updates
US FDA Clears Novavax with Strings Attached: Check What It Means for You
The FDA has approved Novavax’s COVID-19 vaccine, Nuvaxovid, for adults aged 65+ and high-risk individuals 12–64. Unlike mRNA vaccines, it uses a protein-based method for traditional immune protection. With distribution expected in Fall 2025, this approval offers a new option for patients who prefer or require an alternative.
